首页> 美国卫生研究院文献>The Journal of Experimental Medicine >Identification of Lymphomyeloid Primitive Progenitor Cells in Fresh Human Cord Blood and in the Marrow of Nonobese Diabetic–Severe Combined Immunodeficient (NOD-SCID) Mice Transplanted with Human CD34+ Cord Blood Cells
【2h】

Identification of Lymphomyeloid Primitive Progenitor Cells in Fresh Human Cord Blood and in the Marrow of Nonobese Diabetic–Severe Combined Immunodeficient (NOD-SCID) Mice Transplanted with Human CD34+ Cord Blood Cells

机译:移植人CD34 +脐带血细胞的新鲜人脐带血和非肥胖型糖尿病-重症合并免疫缺陷(NOD-SCID)小鼠骨髓中的淋巴细胞原代祖细胞的鉴定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Transplantation of genetically marked donor cells in mice have unambiguously identified individual clones with full differentiative potential in all lymphoid and myeloid pathways. Such evidence has been lacking in humans because of limitations inherent to clonal stem cell assays. In this work, we used single cell cultures to show that human cord blood (CB) contains totipotent CD34+ cells capable of T, B, natural killer, and granulocytic cell differentiation. Single CD34+ CD19Thy1+ (or CD38) cells from fresh CB were first induced to proliferate and their progeny separately studied in mouse fetal thymic organotypic cultures (FTOCs) and cocultures on murine stromal feeder layers. 10% of the clones individually analyzed produced CD19+, CD56+, and CD15+ cells in stromal cocultures and CD4+CD8+ T cells in FTOCs, identifying totipotent progenitor cells. Furthermore, we showed that totipotent clones with similar lymphomyeloid potential are detected in the bone marrow of nonobese diabetic severe combined immunodeficient (NOD-SCID) mice transplanted 4 mo earlier with human CB CD34+ cells. These results provide the first direct demonstration that human CB contains totipotent lymphomyeloid progenitors and transplantable CD34+ cells with the ability to reconstitute, in the marrow of recipient mice, the hierarchy of hematopoietic compartments, including a compartment of functional totipotent cells. These experimental approaches can now be exploited to analyze mechanisms controlling the decisions of such primitive human progenitors and to design conditions for their ampification that can be helpful for therapeutic purposes.
机译:遗传标记的供体细胞在小鼠中的移植已明确鉴定了在所有淋巴和髓样途径中具有完全分化潜能的单个克隆。由于克隆干细胞测定法固有的局限性,因此在人类中缺乏此类证据。在这项工作中,我们使用单细胞培养来显示人脐带血(CB)包含能T,B,自然杀伤和粒细胞分化的全能CD34 + 细胞。首先诱导新鲜CB中的单个CD34 + CD19 - Thy1 + (或CD38 -)细胞增殖并增殖。它们的后代分别在小鼠胎儿胸腺器官型培养(FTOC)和鼠基质饲养层上的共培养中研究。单独分析的克隆中有10%在基质共培养和CD4 + ,CD56 + 和CD15 + 细胞中产生CD19 + ,CD56 + 。 FTOCs中的sup> CD8 + T细胞,鉴定全能祖细胞。此外,我们发现,在4个月前移植了人CB CD34 + 细胞的非肥胖糖尿病重症合并免疫缺陷(NOD-SCID)小鼠的骨髓中,检测到了具有类似淋巴样细胞潜力的全能克隆。这些结果提供了第一个直接证明,人类CB包含全能淋巴细胞原代细胞和可移植CD34 + 细胞,能够在受体小鼠的骨髓中重建造血区室的层次结构,包括功能区室全能细胞。现在可以利用这些实验方法来分析控制此类原始人类祖细胞决定的机制,并设计用于扩增的条件,这些条件可能有助于治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号